Predicting outcome of children with diffuse intrinsic pontine gliomas using multiparametric imaging

被引:67
作者
Hipp, Sean J. [1 ,2 ,3 ]
Steffen-Smith, Emilie [1 ]
Hammoud, Dima [4 ]
Shih, Joanna H. [5 ]
Bent, Robyn [1 ]
Warren, Katherine E. [1 ]
机构
[1] NCI, Pediat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] Walter Reed Army Med Ctr, Dept Pediat, Washington, DC 20307 USA
[3] Uniformed Serv Univ Hlth Sci, Dept Pediat, Bethesda, MD 20814 USA
[4] NIH, Dept Diagnost Radiol, Ctr Clin, Bethesda, MD 20892 USA
[5] NCI, Biometr Res Branch, Div Canc Treatment & Diag, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
diffuse intrinsic pontine glioma; MR spectroscopy; pediatric; prognosis; susceptibility perfusion; PEDIATRIC BRAIN-TUMORS; STEM GLIOMAS; ADULTS; MRI;
D O I
10.1093/neuonc/nor076
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Noninvasive evaluation using MRI is the primary means to routinely assess children with diffuse intrinsic pontine gliomas (DIPGs). However, no standard MR sequence has correlated with outcome in these patients. In this study, patients with DIPGs were assessed to determine the combined prognostic value via dynamic susceptibility contrast (DSC) MRI, single-voxel spectroscopy (SVS), multivoxel MR spectroscopy (MRS), and T1-weighted post-gadolinium imaging. Eligible patients had clinical and radiographic findings consistent with a DIPG. Imaging studies were acquired on a 1.5T MRI at various time points during each patient's course. Data were evaluated using a Cox proportional hazard model, a time-dependent covariant Cox model, a Wald test, and a Kaplan-Meier analysis. Ninety-eight studies were performed on 34 patients of median age 5.5 years. Median survival from diagnosis was 468 days. At baseline imaging only, increased ratio of choline to N-acetylaspartate (Cho:NAA) on SVS and increased perfusion on DSC-MRI each predicted shorter survival (relative risk [RR] = 1.48, P = .015 and RR = 4.91, P = .0012, respectively). When analyzing all subsequent time points, increased maximum Cho:NAA on MRS (RR = 1.45, P = .042), increased Cho:NAA on SVS (RR = 1.69, P = .003), increased perfusion (RR = 4.68, P = .0016), and the presence of enhancement (RR = 5.69, P = .022) each predicted shorter survival. Kaplan-Meier analysis showed shorter survival associated with increased perfusion at baseline (P = .0004). Increased perfusion at any time point predicts a significantly shorter survival in children with DIPG. In addition, enhancement, increased Cho:NAA on SVS, and increased maximum Cho:NAA on chemical shift imaging are predictive of shorter survival over time. Routine baseline and subsequent imaging for children with DIPG should, at minimum, incorporate DSC-MRI and SVS.
引用
收藏
页码:904 / 909
页数:6
相关论文
共 19 条
[1]  
[Anonymous], 2010, CBTRUS STAT REP PRIM
[2]  
COX DR, 1972, J R STAT SOC B, V34, P187
[3]   MULTISECTION PROTON MR SPECTROSCOPIC IMAGING OF THE BRAIN [J].
DUYN, JH ;
GILLEN, J ;
SOBERING, G ;
VANZIJL, PCM ;
MOONEN, CTW .
RADIOLOGY, 1993, 188 (01) :277-282
[4]   Conventional MRI cannot predict survival in childhood diffuse intrinsic pontine glioma [J].
Hargrave, Darren ;
Chuang, Nathaniel ;
Bouffet, Eric .
JOURNAL OF NEURO-ONCOLOGY, 2008, 86 (03) :313-319
[5]   Inter-observer variability in the measurement of diffuse intrinsic pontine gliomas [J].
Hayward, Robert M. ;
Patronas, Nicolas ;
Baker, Eva H. ;
Vezina, Gilbert ;
Albert, Paul S. ;
Warren, Katherine E. .
JOURNAL OF NEURO-ONCOLOGY, 2008, 90 (01) :57-61
[6]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[7]  
Klein JP, 2003, Techniques for censored and truncated data, V2nd
[8]   Brainstem gliomas in children and adults [J].
Laigle-Donadey, Florence ;
Doz, Francois ;
Delattre, Jean-Yves .
CURRENT OPINION IN ONCOLOGY, 2008, 20 (06) :662-667
[9]   Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review [J].
Laperriere, N ;
Zuraw, L ;
Cairncross, G .
RADIOTHERAPY AND ONCOLOGY, 2002, 64 (03) :259-273
[10]  
Law M, 2003, AM J NEURORADIOL, V24, P1989